Publicaciones (50) Publicaciones de ALBERTO MUÑOZ LLARENA

2023

  1. Germline heterozygous exons 8–11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

    Hereditary Cancer in Clinical Practice, Vol. 21, Núm. 1

2015

  1. Efficacy and safety of fixed-dose-rate infusions of gemcitabine plus erlotinib for advanced pancreatic cancer

    Journal of Analytical Oncology, Vol. 4, Núm. 1, pp. 44-51

2014

  1. Bevacizumab in combination with FOLFIRI in the first-line treatment of patients with advanced colorectal cancer: A single-institution experience

    Journal of Analytical Oncology, Vol. 3, Núm. 1, pp. 26-32

  2. Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer

    PLoS ONE, Vol. 9, Núm. 10

  3. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

    Oncology Research, Vol. 21, Núm. 4, pp. 181-191

2013

  1. Phase ii study of irinotecan in combination with capecitabine on a 3-weekly schedule as first-line chemotherapy for patients with metastatic or locally advanced colorectal cancer

    Journal of Analytical Oncology, Vol. 2, Núm. 3, pp. 151-159

  2. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells

    Molecular Cancer, Vol. 11

2010

  1. Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma

    Tumori, Vol. 96, Núm. 3, pp. 405-410

2008

  1. Prognostic factors in cancer of unknown primary site

    Clinical and Translational Oncology

2007

  1. Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer [3]

    Acta Oncologica

  2. Factores pronósticos en metástasis pulmonares resecables de carcinoma colorrectal

    Archivos de Bronconeumologia, Vol. 43, Núm. 6, pp. 309-316

  3. Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer [5]

    Annals of Oncology

2006

  1. Metastatic non-small-cell lung carcinoma successfully treated with pre-operative chemotherapy and bilateral adrenalectomy

    Japanese Journal of Clinical Oncology, Vol. 36, Núm. 11, pp. 731-734

  2. Oxaliplatin overdosage successfully recovered with mild toxicities [1]

    Acta Oncologica

  3. Paclitaxel for progressive basal cell carcinoma [4]

    Journal of the American Academy of Dermatology, Vol. 54, Núm. 2 SUPPL.

  4. To the editor [17]

    New England Journal of Medicine

2005

  1. Acrokeratosis paraneoplastica (Bazex syndrome) preceeding the diagnosis of metastatic squamous cell carcinoma of the esophagus [8]

    Journal of the American Academy of Dermatology, Vol. 52, Núm. 4, pp. 711-712

  2. Biweekly administration of cisplatin/gemcitabine in advanced nonsmall cell lung cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 28, Núm. 5, pp. 501-507

  3. Extravasation of docetaxel: A red hand syndrome

    Archives of Dermatology